{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:53:50Z","timestamp":1785336830833,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ajo.2020.04.008","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T19:16:02Z","timestamp":1586632562000},"page":"110-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials"],"prefix":"10.1016","volume":"216","author":[{"given":"Thomas V.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D.","family":"Jampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","author":"Van Veldhuisen","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2020.04.008_bib2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression - Results from the early manifest glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","author":"Alward","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.04.008_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study - A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2020.04.008_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-158-4-201302190-00008","article-title":"Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Boland","year":"2013","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ajo.2020.04.008_bib7","first-page":"949","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae guidelines","volume":"125","author":"Prum","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs - a meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","article-title":"Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines","volume":"115","author":"Stewart","year":"2008","journal-title":"Ophthalmology"},{"issue":"4-5","key":"10.1016\/j.ajo.2020.04.008_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","article-title":"Medication adherence in patients with ocular hypertension or glaucoma","volume":"14","author":"Robin","year":"2019","journal-title":"Expert Rev Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2020.04.008_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jcm5090079","article-title":"Adherence to glaucoma medications over 12\u00a0months in two US community pharmacy chains","volume":"5","author":"Feehan","year":"2016","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.ajo.2020.04.008_bib12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/eye.2016.103","article-title":"Glaucoma treatment adherence at a United Kingdom general practice","volume":"30","author":"Tse","year":"2016","journal-title":"Eye"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib13","first-page":"808","article-title":"Predictors of nonadherence to topical intraocular pressure reduction medications among Medicare members: a claims-based retrospective cohort study","volume":"22","author":"Sheer","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.ajo.2020.04.008_bib14","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","article-title":"Persistence of topical glaucoma medication: a nationwide population-based cohort study in Taiwan","volume":"132","author":"Hwang","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2020.04.008_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/OPTH.S49467","article-title":"Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions","volume":"8","author":"Campbell","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2020.04.008_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2415-10-5","article-title":"Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy","volume":"10","author":"Reardon","year":"2010","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2020.04.008_bib18","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ajo.2005.09.011","article-title":"Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data","volume":"141","author":"Wilensky","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.04.008_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ophtha.2009.01.021","article-title":"Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma","volume":"116","author":"Friedman","year":"2009","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2008.09.004","article-title":"Adherence with topical glaucoma medication monitored electronically: the Travatan Dosing Aid study","volume":"116","author":"Okeke","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","article-title":"The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study","volume":"127","author":"Newman Casey","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2020.04.008_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/OPTH.S33578","article-title":"Comparison of timolol 0.5%\u00a0+ brimonidine 0.2%\u00a0+ dorzolamide 2% versus timolol 0.5%\u00a0+ brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension","volume":"6","author":"Baiza-Duran","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2020.04.008_bib23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/OPTH.S19999","article-title":"Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost","volume":"5","author":"Fechtner","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00061198-200404000-00008","article-title":"Is addition of a third or fourth antiglaucoma medication effective?","volume":"13","author":"Neelakantan","year":"2004","journal-title":"J Glaucoma"},{"issue":"8","key":"10.1016\/j.ajo.2020.04.008_bib25","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0161-6420(99)90461-X","article-title":"Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy","volume":"106","author":"thoe Schwartzenberg","year":"1999","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2020.04.008_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00061198-200106000-00014","article-title":"Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial","volume":"10","author":"Lee","year":"2001","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IJG.0000000000000987","article-title":"The more, the better? The usefulness of brimonidine as the fourth antiglaucoma eye drop","volume":"27","author":"Bro","year":"2018","journal-title":"J Glaucoma"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaophthalmol.2013.7677","article-title":"Effectiveness of intraocular pressure-lowering medication determined by washout","volume":"132","author":"Jampel","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2020.04.008_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ophtha.2018.05.012","article-title":"A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study","volume":"126","author":"Samuelson","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2020.04.008_bib30","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.ophtha.2016.06.032","article-title":"Two-year COMPASS trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts","volume":"123","author":"Vold","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/jop.2012.0186","article-title":"Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis","volume":"29","author":"Quaranta","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2020.04.008_bib32","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.survophthal.2008.08.011","article-title":"A review of additivity to prostaglandin analogs: fixed and unfixed combinations","volume":"53","author":"Tabet","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2020.04.008_bib33","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1111\/aos.13568","article-title":"Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis","volume":"96","author":"Li","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"30","key":"10.1016\/j.ajo.2020.04.008_bib34","doi-asserted-by":"crossref","first-page":"e16597","DOI":"10.1097\/MD.0000000000016597","article-title":"Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis","volume":"98","author":"Tang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.ajo.2020.04.008_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","article-title":"Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials","volume":"17","author":"Aptel","year":"2008","journal-title":"J Glaucoma"},{"issue":"8","key":"10.1016\/j.ajo.2020.04.008_bib36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1755-3768.2009.01852.x","article-title":"Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial","volume":"89","author":"Heijl","year":"2011","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.04.008_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ophtha.2007.08.010","article-title":"Factors associated with intraocular pressure before and during 9 years of treatment in the collaborative initial glaucoma treatment study","volume":"115","author":"Musch","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2020.04.008_bib38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ajo.2004.07.036","article-title":"Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study","volume":"138","author":"Brandt","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/IJG.0b013e31814b9938","article-title":"Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications","volume":"17","author":"Johnson","year":"2008","journal-title":"J Glaucoma"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/bjo.2010.196899","article-title":"The relationship between corneal hysteresis and the magnitude of intraocular pressure reduction with topical prostaglandin therapy","volume":"96","author":"Agarwal","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2020.04.008_bib41","first-page":"1389","article-title":"Effect of corneal thickness on intraocular pressure measurements with the pneumotonometer, Goldmann applanation tonometer, and Tono-Pen","volume":"43","author":"Bhan","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.124.4.471","article-title":"Effect of central corneal thickness, corneal curvature, and axial length on applanation tonometry","volume":"124","author":"Kohlhaas","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2020.04.008_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/jop.2013.0196","article-title":"Effects of long-term topical prostaglandin therapy on central corneal thickness","volume":"30","author":"Maruyama","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bjophthalmol-2016-308432","article-title":"The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma","volume":"101","author":"Meda","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"10192","key":"10.1016\/j.ajo.2020.04.008_bib45","first-page":"E1","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","volume":"394","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2020.04.008_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/aos.13790","article-title":"Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study","volume":"96","author":"Linden","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2020.04.008_bib47","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/IJG.0b013e31825af0eb","article-title":"The effect of selective laser trabeculoplasty on aqueous humor dynamics in patients with ocular hypertension and primary open-angle glaucoma","volume":"22","author":"Beltran-Agullo","year":"2013","journal-title":"J Glaucoma"},{"issue":"3","key":"10.1016\/j.ajo.2020.04.008_bib48","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1167\/iovs.16-20710","article-title":"Mechanism of action of selective laser trabeculoplasty and predictors of response","volume":"58","author":"Gulati","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2020.04.008_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","article-title":"Determinants of adherence to glaucoma medical therapy in a long-term patient population","volume":"18","author":"Djafari","year":"2009","journal-title":"J Glaucoma"},{"issue":"4","key":"10.1016\/j.ajo.2020.04.008_bib50","doi-asserted-by":"crossref","first-page":"E386","DOI":"10.1097\/IJG.0000000000000380","article-title":"The Maccabi Glaucoma Study: treatment patterns and persistence with glaucoma therapy in a large Israeli health maintenance organization","volume":"25","author":"Goldshtein","year":"2016","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaophthalmol.2014.857","article-title":"Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing the Automated Dosing Reminder Study","volume":"132","author":"Boland","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10792-018-0820-7","article-title":"A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan","volume":"39","author":"Tsumura","year":"2019","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1120672118772517","article-title":"Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia","volume":"29","author":"Anbesse","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2020.04.008_bib54","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence: a cross-sectional survey","volume":"122","author":"Newman Casey","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.joco.2017.09.002","article-title":"Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India","volume":"30","author":"Rajurkar","year":"2018","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.04.008_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/ICU.0b013e3283360b7e","article-title":"Gender and glaucoma: what we know and what we need to know","volume":"21","author":"Vajaranant","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2020.04.008_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archopht.122.3.374","article-title":"Does sex matter in glaucoma?","volume":"122","author":"Higginbotham","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2020.04.008_bib58","series-title":"Glaucoma Surgery: World Glaucoma Association Consensus Series 11","year":"2019"},{"key":"10.1016\/j.ajo.2020.04.008_bib59","series-title":"Guidance for Industry and Food and Drug Administration Staff: United States Food and Drug Administration","article-title":"Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices","year":"2015"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420301756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420301756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:42:09Z","timestamp":1762080129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939420301756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":59,"alternative-id":["S0002939420301756"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2020.04.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2020.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}